Ablynx.com / Homepage

Three-dimensional structure of a Nanobody^®(modeled on the VHH with pdb-code 1U0Q, Cambillau et al). The target molecule is recognized by the surface formed by three hypervariable regions located at the top of the molecule (in green, cyan and blue). Hallmarks, amino acid residues that further differentiate a camelid VHH from a human VH, can be located at different positions within the framework regions, and here are coloured red, pink and magenta.

Welcome to Ablynx

Ablynx, a biopharmaceutical company with headquarters in Ghent, Belgium, is engaged in the discovery and development of Nanobodies^® to treat a range of serious human diseases. Nanobodies^® are a novel class of antibody-derived therapeutic proteins. Because of their small size, unique structure and extreme stability, Nanobodies^® combine the advantages of conventional antibody therapeutics with the key features of small-molecule drugs.

The power of Ablynx's discovery platform has resulted in a Nanobody^® development candidate. Ablynx’s lead programme,

ALX-0081, became the first ever single domain antibody to enter clinical trials and Ablynx reported the final positive results from its Phase I study in December 2007 and will accelerate ALX-0081 to a Phase Ib multiple-dose study directly in the target patient population rather than healthy volunteers.